<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html><head><meta http-equiv="content-type" content="text/html; charset=utf-8"/><meta name="viewport" content="width=device-width, initial-scale=0.8"/><title>Sartans</title><link rel="stylesheet" type="text/css" href="scribble.css" title="default"/><link rel="stylesheet" type="text/css" href="manual-style.css" title="default"/><link rel="stylesheet" type="text/css" href="manual-racket.css" title="default"/><script type="text/javascript" src="scribble-common.js"></script><script type="text/javascript" src="manual-racket.js"></script><!--[if IE 6]><style type="text/css">.SIEHidden { overflow: hidden; }</style><![endif]--></head><body id="scribble-racket-lang-org"><div class="tocset"><div class="tocview"><div class="tocviewlist tocviewlisttopspace"><div class="tocviewtitle"><table cellspacing="0" cellpadding="0"><tr><td style="width: 1em;">&bull;</td><td></td><td><a href="" class="tocviewselflink" data-pltdoc="x">Sartans</a></td></tr></table></div></div></div><div class="tocsub"><table class="tocsublist" cellspacing="0"><tr><td><span class="tocsublinknumber"></span><a href="#%28part._.Sartans%29" class="tocsubseclink" data-pltdoc="x">Sartans</a></td></tr></table></div></div><div class="maincolumn"><div class="main"><div class="versionbox"><span class="versionNoNav">7.9</span></div><h2><a name="(part._.Sartans)"></a>Sartans</h2><p>Les sartans bloquent les recepteurs AT1 a l&rsquo;angiotensine II
mais ne s&rsquo;opposent pas a la synthese d&rsquo;angiotensine II
Ils peuvent en revanche entrainer une hyperkaliemie,
des angioedemes.
Ils s&rsquo;administrent par voie orale</p><ul><li><p>Diminution de la perfusion renale</p></li></ul></div></div><div id="contextindicator">&nbsp;</div></body></html>